Mobile website
Expert Forum
Clinical key issues and countermeasures of CAR-T cell therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Since 2017, twelve chimeric antigen receptor gene-modified T lymphocyte (CAR-T cell) products have been approved for the treatment of hematological malignancies, including relapsed/refractory acute B lymphoblastic leukemia (B-ALL), specific subtypes of B cell lymphoma, and multiple myeloma. However, CAR-T cell therapy faces numerous challenges in its clinical application, such as resistance, lengthy production cycles, high individuation and costs in hematological tumors, and tumor heterogeneity/antigen escape, insufficient infiltration capability, immunosuppressive microenvironments, and poor therapeutic response in solid tumors. With the in-depth exploration of tumor immunology and the development of genetic engineering technology, various new strategies have been attempted to enhance the efficacy and generalizability of CAR-T cell therapy. This paper presents a commentary on CAR-T cell therapy, with a focus on key clinical issues and corresponding countermeasures, providing valuable insights for future basic research and clinical transformation of CAR-T cell therapy.
Keywords:
Project Supported:
Clc Number:
